Ann: FY23 Full Year Results Presentation, page-14

Having questioned the company, here are my two cents regarding capacity:

• The Myriad, Symphony and Enivo products, which will be the significant future growth drivers, use fewer sheep stomachs per unit than Ovitex.

• Aroa will distribute Myriad, Symphony and Enivo itself rather than through a partner like TELA Bio, meaning they retain all the revenues.

• New Zealand has over 20 million sheep, and Aroa said they use less than 2% of that yearly.

• The $100 million revenue capacity figure is old. It was announced before the recent better-than-expected traction of the products Aroa sells directly, so I suspect it's higher now. Regardless, given the above, future capacity per million revenue should be much cheaper than in the past.